Longeveron Inc. Common Stock (LGVN) is a publicly traded Healthcare sector company. As of May 21, 2026, LGVN trades at $0.72 with a market cap of $21.06M and a P/E ratio of -0.27. LGVN moved +8.06% today. Year to date, LGVN is +23.64%; over the trailing twelve months it is -47.28%. Its 52-week range spans $0.48 to $2.48. Analyst consensus is buy with an average price target of $5.50. Rallies surfaces LGVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Longeveron Reports Positive Phase 2b Frailty Data in Cell Stem Cell: Longeveron published positive Phase 2b age-related frailty results in Cell Stem Cell this February, marking a clinical milestone for its cell-based anti-aging therapy. These data position the company within the global longevity biotech market, projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034.
| Metric | Value |
|---|---|
| Price | $0.72 |
| Market Cap | $21.06M |
| P/E Ratio | -0.27 |
| EPS | $-2.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.48 |
| 52-Week Low | $0.48 |
| Volume | 11 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.39M |
| Net Income | $-15.97M |
| Gross Margin | 78.76% |
3 analysts cover LGVN: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $5.50.